Table 1.
Future HSCT Clinical Trials
| Principal Investigator(s) | Location | Number of Patients | Type of MS | Intensity of Conditioning | Status of Trial | ClinicalTrials.gov Reference # |
|---|---|---|---|---|---|---|
| Freedman and Atkins [49] | Ottawa Hospital Research Institute | 24 | Only RRMS and SPMS | High | Completed Awaiting Results | NCT01099930 |
| Burt | Northwestern University | 110 (projected) | Acute Inflammatory RRMS (failing conventional therapy) | Low | Recruiting Patients | NCT00273364 |
| Nash and Bown http://www.halt-ms.org | National Institute of Allergy and Infectious Disease (NIAID) | 25 | RRMS or PRMS | Intermediate | Ongoing | NCT00288626 |
| National Institute of Neurological Disorders and Stroke | Northwestern University and John Hopkins University | 34 | All types | Low | Completed | NCT00342134 |
| Lim | Texas Oncology Cancer Center | 50 (projected) | All types except PPMS (failing conventional therapy) | Low | Recruiting Patients | NCT01679041 |
| Scolding | Frenchay Hospital | 80 (projected) | PPMS or SPMS | None | Not yet Recruiting | NCT01815632 |
Relapsing-Remitting Multiple Sclerosis (RRMS); Secondary Progressive Multiple Sclerosis (SPMS); Primary Progressive Multiple Sclerosis (PPMS); Progressive-Relapsing Multiple Sclerosis (PRMS). Information complied from http://clinicaltrials.gov.